Placulumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NamePlaculumab
Drug Alias Name普库人单抗placulumabum普拉鲁单抗CEP-37247PN-0621 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsSciaticaArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDomantis LtdPeptech Uk
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArana Therapeutics LtdCephalon
Active IndicationsN/A
Inactive IndicationsSciaticaArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG